1. Trujillo, K. A. and Akil, H. (1991) Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 251, 85-87.

2. Marek, P., Ben Eliyahu, S., Vaccarino, A. L., and Liebeskind, J. C. (1991) Delayed application of MK-801 attenuates development of morphine tolerance in rats. Brain Res. 558, 163-165.

3. Marek, P., Ben Eliyahu, S., Gold, M., and Liebeskind, J. C. (1991) Excitatory amino acid antagonists (kynurenic acid and MK-801) attenuate the development of morphine tolerance in the rat. Brain Res. 547, 77-81.

4. Ben Eliyahu, S., Marek, P., Vaccarino, A. L., Mogil, J. S., Sternberg, W. F., and Liebeskind, J. C. (1992) The NMDA receptor antagonist MK-801 prevents long-lasting non-associative morphine tolerance in the rat. Brain Res. 575, 304-308.

5. Bilsky, E. J., Inturrisi, C. E., Sadee, W., Hruby, V. J., and Porreca, F. (1996) Competitive and non-competitive NMDA antagonist block the development of antinociceptive tolerance to morphine, but not to selective mu or delta opioid agonists in mice. Pain 68, 229-237.

6. Elliott, K. J., Hynansky, A., and Inturrisi, C. E. (1994) Dextromethorphan attenuates and reverses morphine tolerance. Pain 59, 361-368.

7. Wong, C. S., Hsu, M. M., Chou, Y. Y., Tao, P. L., and Tung, C. S. (2000) Morphine tolerance increases [3H]MK-801 binding affinity and constitutive neuronal nitric oxide synthase expression in the rat spinal cord. Br. J. Anaesth. 85, 587-591.

8. Grisel, J. E., Watkins, L. R., and Maier, S. F. (1996) Associative and non-associative mechanisms of morphine analgesic tolerance are neurochemically distinct in the rat spinal cord. Psychopharmacology (Berl.) 128, 248-255.

9. Jhamandas, K. H., Marsala, M., Ibuki, T., and Yaksh, T. L. (1996) Spinal amino acid release and precipitated withdrawal in rats chronically infused with spinal morphine. J. Neurosci. 16, 2758-2766.

10. Lutfy, K., Shen, K. Z., Woodward, R. M., and Weber, E. (1996) Inhibition of morphine tolerance by NMDA receptor antagonists in the formalin test. Brain Res. 731,171-181.

11. Manning, B. H., Mao, J., Frenk, H., Price, D. D., and Mayer, D. J. (1996) Continuous co-administration of dextromethorphan or MK-801 with morphine: attenuation of morphine dependence and nalixone-reversible attenuation of morphine tolerance. Pain 67, 79-80.

12. Mao, J., Price, D. D., Caruso, F. S., and Mayer, D. J. (1996) Oral administration of dextromethorphan prevents the development of morphine tolerance and dependence in rats. Pain 67, 361-368.

13. Popik, P. and Skolnick, P. (1996) The NMDA antagonist memantine blocks the expression and maintenance of morphine dependence. Pharmacol. Biochem. Behav. 53, 791-797.

14. Tokuyama, S., Wakabayashi, H., and Ho, I. K. (1996) Direct evidence for a role of glutamate in the expression of the opioid withdrawal syndrome. Eur. J. Pharamacol. 295,123-129.

15. Wong, C. S., Cherng, C. H., Luk, H. N., Ho, S. T., and Tung, C. S. (1996) Effects of NMDA receptor antagonists on inhibition of morphine tolerance in rats: binding at mu-opioid receptors. Eur. J. Pharmacol. 297, 27-33.

16. Tiseo, P. J. and Inturrisi, C. E. (1993) Attenuation and reversal of morphine tolerance by the competitive N-methyl-d-aspar-tate receptor antagonist, LY274614. J. Pharmacol. Exp. Ther. 264, 1090-1096.

17. Lufty, K., Shen, K. Z., Kwon, I. S., Cai, S. X., Woodward, R. M., Keana, J. F., et al. (1995) Blockade of morphine tolerance by ACEA-1328, a noval NMDA receptor/glycine site antagonist. Eur. J. Pharmacol. 273,187-189.

18. Gonzalez, P., Cabello, P., Germany, A., Norris, B., and Contreras, E. (1997) Decrease of tolerance to, and physical dependence on morphine by, glutamate receptor antagonists. Eur. J. Pharmacol. 332, 257-262.

19. Davis, A. M., and Inturrisi, C. E. (1999) ¿-Methadone blocks morphine tolerance and N-methyl-d-aspartate-induced hyperalgesia. J. Pharmacol. Exp. Ther. 289, 1048-1053.

20. Lutfy, K., Doan, P., and Weber E. (1999) ACEA-128, an NMDA receptor/glycine site antagonist, acutely potentiates antinociciption and chronically attenuates tolerance induced by morphine. Pharmacol. Res. 40, 435-442.

21. Christensen, D., Guilbaud, G., and Kayser, V. (2000) Complete prevention but stimulus-dependent reversion of morphine tolerance by the glycine/NMDA receptor antagonist (+)-HA966 in neuropathic rats. Anesthesiology 92, 786-794.

22. Belozertseva, I. V., Danysz, W., and Bespalov, A. Y. (2000) Effects of a short-acting NMDA receptor antagonist MRZ 2/576 on morphine tolerance and development in mice. Naunyn-Schmiedebergs Arch. Pharmacol. 361, 573-577.

23. Houghton, A. K., Parsons, C. G., and Headley, P. M. (2001) Mrz 2/579, a fast kinetic NMDA channel blocker, reduces the development of morphine tolerance in awake rats. Pain 91, 201-207.

24. Allen, R. M. and Dykstra, L. A. (2000) Attenuation of mu-opioid tolerance and cross-tolerance by the competitive N-methyl-d-aspartate receptor antagonist LY235959 is related to tolerance and cross-tolerance magnitude. J. Pharmacol. Exp. Ther. 295,1012-1021.

25. Larson, A. A., Kovacs, K. J., and Spartz, A. K. (2000) Intrathecal Zn2+ attenuates morphine antinociception and the development of acute tolerance. Eur. J. Pharmacol. 407, 267-272.

26. Popik, P. and Kozela, E. (1999) Clinically available NMDA antagonist, memantine, attenuates tolerance to analgesic effects of morphine in a mouse tail flick test. Pol. J. Pharmacol. 51, 223-231.

27. Popik, P., Kozela, E., and Danysz, W. (2000) Clinically available NMDA receptor antagonists memantine and dextromethorphan reverse existing tolerance to the antinociceptive effects of morphine in mice. Naunyn-Schmiedebergs Arch. Pharmacol. 361, 425-432.

28. Chen, Z. R., Irvine, R. J., Somogyi, A. A., and Bochner, F. (1991) Mu receptor binding of some commonly used opioids and their metabolites. Life Sci. 48, 2165-2171.

29. Emmerson, P. J., Liu, M. R., Woods, J. H., and Medzihradsky, F. (1994) Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes. J. Pharmacol. Exp. Ther. 271, 1630-1637.

30. Mignat, C., Wille, U., and Ziegler, A. (1995) Affinity profiles of morphine, codeine, dihydrocodeine and their glucuronides at opioid receptor subtypes. Life Sci. 56, 793-799.

31. Mao, J., Price, D. D., Lu, J., and Mayer, D. J. (1998) Antinociceptive tolerance to the mu-opioid agonist DAMGO is dose-dependently reduced by MK-801 in rats. Neurosci. Lett. 250, 193-196.

32. Tanganelli, S., Antonelli, T., Morari, M., Bianchi, C., and Beani, L. (1991) Glutamate antagonists prevent morphine withdrawal in mice and guinea pigs. Neurosci. Lett. 122, 270-272.

33. Christensen, D., Guilbaud, G., and Kayser, V. (2000) The effect of the glycine/NMDA receptor antagonist, (+)-HA966, on morphine dependence in neuropathic rats. Neuropharmacology 39,1589-1595.

34. Ibuki, T., Dunbar, S. A., and Yaksh, T. L. (1997) Effect of transient naloxone antagonism on tolerance development in rats receiving continous spinal morphine infusion. Pain 70, 125-132.

35. Bhargava, H. N. and Zhao, G. M. (1996) Effects of N-methyl-d-aspartate receptor antagonists on the analgesia and tolerance to D-Ala2, Glu4 deltorphin II, a delta 2-opioid receptor agonist in mice. Brain Res. 719, 56-61.

36. Zhao, G. M. and Bhargava, H. N. (1996) Effect of antagonism of the NMDA receptor on tolerance to <D-Pen2,D-Pen5> enkephalin, a delta 1-opioid receptor agonist. Peptides 17, 233-236.

37. Kolesnikov, Y. A., Maccechini, M. L., and Pasternak, G. W. (1994) 1-Aminocyclopropane carboxylic acid (ACPC) prevents mu and delta opioid tolerance. Life Sci. 55, 1393-1398.

38. Elliott, K., Minami, N., Kolesnikov, Y. A., Pasternak, G. W., and Inturrisi, C. E. (1994) The NMDA receptor antagonists, LY274614 and MK-801, and the nitric oxide synthase inhibitor, NG-nitro-l-arginine, attenuate analgesic tolerance to the mu-opioid morphine but not to kappa opioids. Pain 56, 69-75.

39. Bhargava, H. N. and Thorat, S. N. (1994) Effect of dizocilpine (MK-801) on analgesia and tolerance induced by U-50, 488H, a kappa-opioid receptor agonist, in the mouse. Brain Res. 649, 111-116.

40. Chen, L., Gu, Y., and Huang, L. Y. (1995) The mechanism of action for the block of NMDA receptor channels by the opioid peptide dynorphin. J. Neurosci. 15, 4602-4611.

41. Randic, M., Cheng, G., and Kojic, L. (1995) kappa-opioid receptor agonists modulate excitatory transmission in substantia gelatinosa neurons of the rat spinal cord. J. Neurosci. 15, 6809-6826.

42. Mayer, D. J., Mao, J., and Price, D. D. (1995) The development of morphine tolerance and dependence in associated with translocation of protein kinase C. Pain 61, 365-374.

43. Mao, J., Price, D. D., Phillips, L. L., Lu, J., and Mayer, D. J. (1995) Increases in protein kinase C gamma immunoreactivity in the spinal cord of rats associated with tolerance to the analgesic effects of morphine. Brain Res. 677, 257-267.

44. Mao, J., Price, D. D., and Mayer, D. J. (1994) Thermal hyperalgesia in association with the development of morphine tolerance in rats: Roles of excitatory amino acid receptors and protein kinase C. J. Neurosci. 14, 2301-2312.

45. Narita, M., Mizoguchi, H., Kampine, J. P., and Tseng, L. F. (1996) Role of protein kinase C in desensitization of spinal delta-opioid-mediated antinociception in the mouse. Br. J. Pharmacol. 118, 1829-1835.

46. Narita, M., Mizoguchi, H., and Tseng, L. F. (1995) Inhibition of protein kinase C, but not of protein kinase A, blocks the development of acute antinociceptive tolerance to an intrathecally administered mu-opioid receptor agonist in the mouse. Eur. J. Pharmacol. 280, R1-R3.

47. Bilsky, E. J., Bernstein, Z., Wang, Z., Sadee, W., and Porreca, F. (1996) Effects of naloxone and d-phe-Cys-Tyrd-Trp-Arg-Thr-Phe-Thr-NH2 and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice. J. Pharmacol. Exp. Ther. 277, 484-490.

48. Mestek, A., Hurley, J. H., Bye, L. S., Campbell, A. D., Chen, Y., Tian, M., et al. (1995) The human mu opioid receptor: modulation of functional desensitization by calcium/calmodulin-dependent protein kinase and protein kinase C. J. Neurosci. 15, 2396-2406.

49. Gies, E. K., Peters, D. M., Gelb, C. R., Knag, K. M., and Peterfreund, R. A. (1998) Regulation of mu opioid receptor mRNA levels by activation of protein kinase C in human SH-SY5Y neuroblastoma cells. Anesthesiology 87, 1127-1138.

50. Mao, J., Price, D. D., Mayer, D. J., and Hayes, R. L. (1992) Pain-related increases in spinal cord membrane-bound protein kinase C following peripheral nerve injury. Brain Res. 588,144-149.

51. Mao, J., Mayer, D. J., Hayes, R. L., and Price, D. D. (1993) Spatial patterns of increased spinal cord membrane-bound protein kinase C and their relation to increases in 14C-2-deoxyglucose metabolic activity in rats with painful peripheral mononeuropathy. J. Neurophysiol. 70, 470-481.

52. Narita, M., Makimura, M., Feng, Y., Hoskins, B., and Ho, I. K. (1994) Influence of chronic morphine treatment on protein kinase C activity: comparison with butorphanol and implication for opioid tolerance. Brain Res. 650, 175-179.

53. Kovoor, A., Celver, J. P., Wu, A., and Chavkin, C. (1998) Agonist induced homologous desensitization of ^-opioid receptors mediated by G protein-coupled receptor kinases is dependent on agonist efficacy. Mol. Pharmacol. 54, 704-711.

54. Kovoor, A., Nappey, V., Kieffer, B. L., and Chavkin, C. (1997) Mu and delta opioid receptors are differentially desensitized by the coexpression of beta-adrenergic receptor kinase 2 and beta-arrestin 2 in Xenopus oocytes. J. Biol. Chem. 272, 27,605-27,611.

55. Kovoor, A., Celver, J., Abdryashitov, R. I., Chavkin, C., and Gurevich, V. V. (1999) Targeted construction of phosphoryla-tion-independent beta-arrestin mutants with constitutive activity in cells. J. Biol. Chem. 274, 6831-6834.

56. Chen, L. and Huang, L. Y. M. (1991) Sustained potentiation of NMDA receptor-mediated glutamate responses through activation of protein kinase C by a ^-opioid. Neuron 7, 319-326.

57. Chen, L. and Huang, L. Y. M. (1992) Protein kinase C reduces Mg2+ block of NMDA-receptor channels as a mechanism of modulation. Nature 356, 521-523.

58. Gracy, K. N., Svingos, A. L., and Pickel, V. M. (1997) Dual ultrastructural localization of mu-opioid receptors and NMDA-type glutamate receptors in the shell of the rat nucleus accumbens. J. Neurosci. 17, 4839-4848.

59. Wang, H., Gracy, K. N., and Pickel, V. M. (1999) |-Opioid and NMDA-type glutamate receptors are often colocalized in spiny neurons within patches of the caudata-putamen nucleus. J. Comp. Neurol. 412, 132-146.

60. Commons, K. G., Van Bockstaele, E. J., and Pfaff, N. W. (1999) Frequent colocalization of mu opioid and NMDA-typer glutamate receptors at postsynaptic sites in periaquaductal gray neurons. J. Comp. Neurol. 408, 549-559.

61. Keniston, L., Mao, J., Price, D. D., Lu, J., and Mayer, D. J. (1998) Soc. Neurosci. Abst. 24, 390.

62. Mao, J., Price, D. D., and Mayer, D. J. (1995) Mechanisms of hyperalgesia and opiate tolerance: A current view of their possible interactions. Pain 62, 259-274.

63. Granados-Soto, V., Kalcheva, I., Hua, X., Newton, A., and Yaksh, T. L. (2000) Spinal PKC activity and expression: role in tolerance produced by continuous spinal morphine infusion. Pain 85, 395-404.

64. Fox, K. and Daw, N. W. (1993) Do NMDA receptors have a critical function in visual cortical plasticity? Trends Neurosci. 16, 116-122.

65. Christie, M. J., Williams, J. T., and North, R. A. (1987) Cellular mechanisms of opioid tolerance: studies in single brain neurons. Mol. Pharmacol. 32, 633-638.

66. Collin, E. and Cesselin, F. (1991) Neurobiological mechanisms of opioid tolerance and dependence. Clin. Neuropharmacol. 14, 465-488.

67. Trujillo, K. A. and Akil, H. (1991) Opiate tolerance and dependence: recent findings and synthesis. New Biologist 3, 915-923.

68. Nestler, E. J. (1992) Molecular Mechanisms of drug addiction. J. Neurosci. 12, 2439-2450.

69. Pasternak, G. W. (1993) Pharmacological mechanisms of opioid analgesics. Clin. Neuropharmacol. 16, 1-18.

70. Loh, H. H., Tao, P. L., and Smith, A. P. (1988) Role of receptor regulation in opioid tolerance mechanisms. Synapse 2, 457-462.

71. Nishino, K., Su, Y. F., Wong, C. S., Watkins, W. D., and Chang, K. J. (1990) Dissociation of mu opioid tolerance from receptor down-regulation in rat spinal cord. J. Pharmacol. Exp. Ther. 253, 67-72.

72. Harada, H., Ueda, H., Katada, T., Ui, M., and Satoh, M. (1990) Phosphorylated |-opiate receptor purified from rat brains lacks functional coupling with Gil, a GTP-binding protein in reconstituted lipid vesicles. Neurosci. Lett. 113, 47-49.

73. Chen, Y. and Yu, L. (1994) Differential regulation by cAMP-dependent protein kinase and protein kinase C of the | opioid receptor coupling to a G protein activated K channel. J. Biol. Chem. 269, 7839-7842.

74. Narita, M., Mizoguchi, H., Nagase, H., Suzuki, T., and Tseng, L. F. (2001) Involvement of spinal protein kinase C-gama in the attenuation of opioid-mu-receptor-mediated G-protein activation after chronic intrathecal administration of [d-Ala2,N-MePhe4,Gly-Ol5]enkephalin. J. Neurosci. 21, 3715-3720.

75. Meller, S. T. and Gebhart, G. F. (1993) Nitric oxide (NO) and nociceptive processing in the spinal cord. Pain 52, 127-136.

76. Sorkin, L. S. (1993) NMDA evokes an l-NAME sensitive spinal release of glutamate and citrulline. NeuroReport 4, 479-482.

77. Montague, P. R., Gancayco, C. D., Winn, M. J., Marchase, R. B., and Friedlander, M. J. (1994) Role of NO production in NMDA receptor-mediated neurotransmitter release in cerebral cortex. Science 263, 973-977.

78. Mao, J., Price, D. D., Zhu, J., Lu, J., and Mayer D. J. (1997) The inhibition of nitric oxide-activated poly(ADP-ribose) synthetase attenuates transsynaptic alteration of spinal cord dorsal horn neurons and neuropathic pain in the rat. Pain 72, 355-366.

79. Azaryan, A. V., Coughlin, L. J., Buzas, B., Clock, B. J., and Cox, B. M. (1996) Effect of chronic cocaine treatment on mu-and delta-opioid receptor mRNA levels in dopaminergically innervated brain regions. J. Neurochem. 66, 443-448.

80. Mayer, D. J., Mao, J., Holt, J., and Price, D. D. (1999) Cellular mechanisms of neuropathic pain, morphine tolerance, and their interactions. Proc. Natl. Acad. Sci. USA 96, 7731-7736.

81. Fundytus, M. E. and Coderre, T. J. (1999) Opioid tolerance and dependence: a new model highlighting the role of metabotropic glutamate receptors. Pain Forum 8, 3-13.

82. Trujillo, K. A. (1999) Cellular and molecular mechanisms of opioid tolerance and dependence. Pain Forum 8, 29-33.

83. Herman, B. H., Vocci, F., and Bridge, P. (1995) The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal: medicationdevelopment issues for opiate addiction. Neuropsychopharmacol-ogy 13, 269-294.

84. Herrero, I., Miras-Potugal, M. T., and Sanche-Prieto, J. (1992) Positive feedback of glutamate exocytosis by metabotropic presynaptic receptor stimulation. Nature 360, 163-166.

85. Mackler, S. A. and Eberwine, J. H. (1991) The molecular biology of addictive drugs. Mol. Neurobiol. 5, 45-58.

86. Mao, J., Price, D. D., and Mayer, D. J. (1995) Experimental mononeuropathy reduces the antinociceptive effects of morphine: implications for common intracellular mechanisms involved in morphine tolerance and neuropathic pain. Pain 61, 353-364.

87. Ossipov, M. H., Lopez, Y., Nichols, M. L., Bian, D., and Porreca, F. (1995) The loss of antinociceptive efficacy of spinal morphine in rats with nerve ligation injury is prevented by reducing spinal afferent drive. Neurosci. Lett. 199, 87-90.

88. Wegert, S., Ossipov, M. H., Nichols, M. L., Bian, D., Vanderah, T. W., Malan, T. P., Jr., et al. (1997) Differential activities of intrathecal MK-801 or morphine to alter responses to thermal and mechanical stimuli in normal and nerve-injured rats. Pain 71, 57-64.

89. Dunbar, S. A. and Pulai, I. J. (1998) Repetitive opioid abstinence causes progressive hyperalgesia sensitive to N-methyl-d-aspartate receptor blockade in the rat. J. Pharmacol. Exp. Ther. 284, 678-686.

90. McNally, G. P. and Westbrook, R. F. (1998) Effects of systemic, intracerebral, or intrathecal administration of an N-methyl-d-aspartate receptor antagonist on associative morphine analgesic tolerance and hyperalgesia in rats. Behav. Neurosci. 112, 966-978.

91. Herman, B. H. and O'Brien, C. P. (1997) Clinical medications development for opiate addiction: focus on nonopioids and opioid antagonists for the amelioration of opiate withdrawal symptoms and relapse prevention. Semin. Neurosci. 9,158-172.

Natural Detox

Natural Detox

Are you looking for a full total body detox? If so, then you might want to try a 10 day detox or some refer to it as the 2-week detox. A 10-day detox is a full body detox that usually means taking several different steps to reach your total body transformation. It might involve a change in diet, exercise and more.

Get My Free Ebook

Post a comment